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LMS

:   leiomyosarcomas

MDT

:   multidisciplinary team

MFS

:   myxofibrosarcomas

PFS

:   progression‐free survival

STS

:   soft tissue sarcomas

UPS

:   undifferentiated pleomorphic sarcomas

Introduction {#ijc32307-sec-0001}
============

Soft tissue sarcomas (STS) are rare tumors accounting for less than 1% of human cancers, with a yearly incidence close to 5.9/100,000.[1](#ijc32307-bib-0001){ref-type="ref"}, [2](#ijc32307-bib-0002){ref-type="ref"}, [3](#ijc32307-bib-0003){ref-type="ref"}, [4](#ijc32307-bib-0004){ref-type="ref"}, [5](#ijc32307-bib-0005){ref-type="ref"} Death due to tumor is frequent in this group of diseases.[5](#ijc32307-bib-0005){ref-type="ref"} While the highest incidence of sarcomas is observed in patients aged between 75 and 84 years with a rate of 16%,[1](#ijc32307-bib-0001){ref-type="ref"}, [5](#ijc32307-bib-0005){ref-type="ref"} elderly patients are often excluded or very poorly represented in clinical trials.[6](#ijc32307-bib-0006){ref-type="ref"} Therefore, little is known about characteristics, treatment and outcomes concerning patients aged over 65, in particular for those over 90 years with STS.[6](#ijc32307-bib-0006){ref-type="ref"}, [7](#ijc32307-bib-0007){ref-type="ref"}

Sarcomas represent a heterogeneous group with over 80 different pathological subtypes.[8](#ijc32307-bib-0008){ref-type="ref"} Sarcoma with "simple genomics" include those with specific translocations, well‐differentiated liposarcomas with 12q amplicon and GIST with tyrosine kinase mutation accounting for 12--20% of cases each; those with "complex genomic" profiles (e.g., undifferentiated pleomorphic sarcomas \[UPS\], leiomyosarcomas \[LMS\] and myxofibrosarcomas \[MFS\]) account for 50% of all STS.[9](#ijc32307-bib-0009){ref-type="ref"}, [10](#ijc32307-bib-0010){ref-type="ref"}, [11](#ijc32307-bib-0011){ref-type="ref"}

The objective of this work was to analyze the presentation and outcome of sarcoma patients over 90 years, a group of patients unreported in the literature, with the aim of providing data which could guide the management of the general elderly patient population with sarcomas.

Patients and Methods {#ijc32307-sec-0002}
====================

NETSARC network {#ijc32307-sec-0003}
---------------

NETSARC is the French reference network for the management of soft tissue and visceral sarcomas, collecting clinical, centrally reviewed pathology, therapeutics and outcome of all sarcoma patients in 26 centers. The registry was approved in October 2009 by the INCa (Institut National du Cancer) and the competent authorities (CNIL) in 2010.[5](#ijc32307-bib-0005){ref-type="ref"} These databases have been approved by the French Ethics Committee and Agency in charge of noninterventional trials: Comité consultatif sur le traitement de l\'information en matière de recherche dans le domaine de la Santé (CCTIRS: number of approval 09.594) and Commission Nationale Informatique et Liberté (CNIL: number of approval 909,510). In the present work, we used information of patients registered from January 1, 2010, to December 2016. Mean follow‐up of this series is 17 months. Patient\'s data (gender, histology, grade, depth, size, localization, treatment, relapse and survival) were collected from the NETSARC database (<https://netsarc.org>).

Statistical analysis {#ijc32307-sec-0004}
--------------------

Collected data were analyzed using IBM SPSS Statistics version 20 (IBM, Paris, France). Chi‐square and Fisher exact tests were performed to analyze the data sets of the different age groups. Survival was plotted according to the Kaplan--Meier method, compared to the log‐rank test. Cox model was used for multivariate analysis of prognostic factors.

Results {#ijc32307-sec-0005}
=======

Population {#ijc32307-sec-0006}
----------

A total of 12,835 incident patients with sarcomas, with 113 (0.9%) patients aged \>90 were registered in the national NETSARC sarcoma database between January 1, 2010, and December 31, 2016. Patients' characteristics are described in Table [1](#ijc32307-tbl-0001){ref-type="table"}. Sarcomas with complex genomics were overrepresented in patients over 90 when compared to patients under 90 (92.0% *vs*. 66.3%, *p* \< 0.001). Undifferentiated pleomorphic sarcoma (UPS), LMS and MFS were the most represented histological subtypes in patients over 90 (Table [1](#ijc32307-tbl-0001){ref-type="table"}). Limb and head and neck sites, and superficial locations were overrepresented in patients over 90 (*p* ≤ 0.001). Male patients were overrepresented in patients aged \>90 while representing close to 25% of French citizen aged \>90.

###### 

Patient characteristics

                                     Age at diagnosis    *p*               
  ---------------------------------- ------------------- ----------------- ------------------------------------------------
  Age at diagnosis (years)                                                 
  Median                             62                  92                
  Range                              0--90               91‐101            
  Sex                                                                      NS[1](#ijc32307-note-0002){ref-type="fn"}
  Female                             6,283 (49·4%)       62 (54·9%)        
  Male                               6,439 (50·6%)       51 (45·1%)        
  Localization at diagnosis                                                
  Trunk                              6,706 (52·7%)       25 (22·1%)        ≤0.001[1](#ijc32307-note-0002){ref-type="fn"}
  Limb                               4,218 (33·2%)       67 (59·3%)        
  *Superior limb*                    *1,092 (8*·*6%)*    *22 (19*·*5%)*    
  *Inferior limb*                    *3,126 (2*·*6%)*    *45 (3*·*8%)*     
  Head & neck                        710 (5·5%)          18 (15·9%)        
  Unknown                            1,088 (8·6%)        3 (2·7%)          
  Histology                                                                
  *Complex genomics*                 *8,431 (66*·*3%)*   *104 (92*·*0%)*   ≤0.001[1](#ijc32307-note-0002){ref-type="fn"}
  UPS                                1,569 (12·3%)       40 (35·4%)        
  LMS                                2,762 (21·7%)       16 (14·2%)        
  Myxofibrosarcoma                   804 (6·3%)          14 (12·4%)        
  Angiosarcoma                       666 (5·2%)          12 (10·6%)        
  DDLPS                              1,506 (11·8%)       11 (9·7%)         
  Undifferentiated sarcoma           768 (6·0%)          10 (8·8%)         
  Rhabdomyosarcoma                   98 (0·7%)           1 (0·9%)          
  Fibrosarcoma                       44 (0·3%)           0 (0%)            
  Liposarcoma pleomorphic            174 (1·4%)          0 (0%)            
  Osteosarcoma                       40 (0%)             0 (0%)            
  *GIST*                             *1,490 (11*·*7%)*   *6 (5*·*3%)*      
  *Translocation sarcoma*            *2,801 (2*2·*0%)*   *3 (2*·*7%)*      
  Ewing                              769 (6·0%)          1 (0·9%)          
  Myxoid LPS                         484 (3·8%)          1 (0·9%)          
  Synovial sarcoma                   635 (5·0%)          1 (0·9%)          
  ESS                                273 (2·1%)          0 (0%)            
  Epithelioid hemangioendothelioma   100 (0·9%)          0 (0%)            
  EMC                                89 (0·7%)           0 (0%)            
  SFT                                451 (3·5%)          0 (0%)            
  Grade                                                                    
  1                                  1,086 (8·5%)        6 (5·3%)          NS[1](#ijc32307-note-0002){ref-type="fn"}
  2                                  3,133 (24·6%)       24 (2·2%)         
  3                                  3,800 (29·9%)       39 (34·5%)        
  Unknown                            4,703 (36·9%)       44 (38·9%)        
  Depth                                                                    \<0.001[1](#ijc32307-note-0002){ref-type="fn"}
  Superficial                        1873 (14·7%)        45 (39·8%)        
  Deep                               8,636 (67·9%)       50 (44·2%)        
  Superficial + deep                 806 (6·3%)          13 (11·5%)        
  Unknown                            1,407 (11·1%)       5 (4·4%)          
  Size                                                                     NS[1](#ijc32307-note-0002){ref-type="fn"}
  \<50 mm                            1,620 (12·7%)       18 (15·9%)        
  ≥50 mm                             3,924 (30·8%)       29 (25·7%)        
  Unknown                            7,178 (56·4%)       66 (58·4%)        
  Previous history of radiotherapy                                         NS[1](#ijc32307-note-0002){ref-type="fn"}
  No                                 12,388 (97·7%)      110 (97·3%)       
  Yes                                294 (2·3%)          3 (2·7%)          
  Previous history of cancer                                               NS[1](#ijc32307-note-0002){ref-type="fn"}
  No                                 8,563 (67·3%)       68 (60·2%)        
  Yes                                1,741 (13·7%)       20 (17·7%)        
  Unknown                            2,418 (19·0%)       25 (22·1%)        
  Known genetic predisposition                                             NS[1](#ijc32307-note-0002){ref-type="fn"}
  No                                 10,181 (80·0%)      88 (77·9%)        
  Yes                                123 (1·0%)          0 (0%)            
  Unknown                            2,418 (19·0%)       25 (2·1%)         
  Metastatic at diagnosis                                                  0.009[1](#ijc32307-note-0002){ref-type="fn"}
  Yes                                1865 (14·7%)        6 (5·3%)          
  No                                 9,664 (76·0%)       89 (78·8%)        
  Unknown                            1,193 (9·4%)        18 (15·9%)        

Italics refer to molecular subtypes of sarcomas.

Chi^2^ test.

(<https://www.insee.fr/fr/statistiques/1892086?sommaire=1912926>), male patients represented 45% of the patients in this age group. Patients \>90 were also less frequently metastatic at initial diagnosis (*p* = 0·009), even when considering only patients who had a CT scan (data not shown). Prior history of cancers and radiotherapy were no more frequent in patients aged over 90 *vs*. younger patients (Table [1](#ijc32307-tbl-0001){ref-type="table"}). Genetic predisposition was observed in none of the 113 patients over 90 *vs*. 123 reported in the remaining population.

Patient management {#ijc32307-sec-0007}
------------------

The adherence to ESMO clinical practice guidelines (2,3) was then analyzed (Table [2](#ijc32307-tbl-0002){ref-type="table"}). While biopsy rate was similar, patients aged over 90 had less frequently appropriate pretreatment imaging than patients under 90 (56.6% *vs*. 75.1%, *p* ≤ 0.001). This was true also when comparing patients aged \>90 to the group of 60--80 or 80--90 (Table [3](#ijc32307-tbl-0003){ref-type="table"}).

###### 

Disease management in patients aged above and under 90

                                         Age at diagnosis                              *p*                                             
  -------------------------------------- --------------------------------------------- ----------------------------------------------- -----------------------------------------------
  *Disease management*                                                                                                                 
  Biopsy performed before surgery                                                      NS[1](#ijc32307-note-0003){ref-type="fn"}       
  Yes                                    8,213 (64·6%)                                 72 (63·7%)                                      
  No                                     3,552 (27·9%)                                 32 (28·3%)                                      
  Unknown                                957 (7·5%)                                    9 (8·0%)                                        
  Imaging performed before surgery                                                     ≤0.001[1](#ijc32307-note-0003){ref-type="fn"}   
  Yes                                    9,552 (75·1%)                                 64 (56·6%)                                      
  No                                     700 (5·5%)                                    14 (12·4%)                                      
  Unknown                                2,470 (19·4%)                                 35 (31·0%)                                      
  Neoadjuvant treatment before surgery                                                 0.045[1](#ijc32307-note-0003){ref-type="fn"}    
  Yes                                    835/3565 (23·4%)                              3/34 (8·8%)                                     
  No                                     2730/3565 (76·6%)                             31/34 (91·2%)                                   
  Total                                  3,565                                         34                                              
  Surgery performed                                                                                                                    ≤0.001[1](#ijc32307-note-0003){ref-type="fn"}
  Yes                                    9,988 (78·5%)                                 68 (60·2%)                                      
  No                                     1,014 (8·0%)                                  23 (20·4%)                                      
  Unknown                                1,720 (13·5%)                                 22 (19·5%)                                      
  Excision margins of first surgery      0.09[1](#ijc32307-note-0003){ref-type="fn"}                                                   
  R0                                     3,910 (30·7%)                                 26 (23%)                                        
  R1                                     2,608 (20·5%)                                 20 (17·7%)                                      
  R2                                     990 (7·8%)                                    9 (8%)                                          
  Unknown                                5,214 (41·0%)                                 58 (51·3%)                                      
  Reexcision after first surgery                                                       NS[1](#ijc32307-note-0003){ref-type="fn"}       
  No                                     11,380 (89·5%)                                105 (92·9%)                                     
  Yes                                    1,342 (10·5%)                                 8 (7·1%)                                        
  Excision margins at second surgery                                                   NS[1](#ijc32307-note-0003){ref-type="fn"}       
  R0                                     993 (7·8%)                                    5 (4·4%)                                        
  R1                                     213 (1·7%)                                    2 (1·8%)                                        
  R2                                     39 (0·3%)                                     0                                               
  Unknown                                97/1342                                       1/8                                             

Chi‐square or Fisher\'s exact test.

###### 

Sarcoma patient characteristics and management across age groups

  Age                                Age at diagnosis (% of the age groups within the series)                                                                              
  ---------------------------------- ---------------------------------------------------------- ------------- --------------- --------------- --------------- ------------ -------------
  Histology                                                                                                                                                                
  *Complex genomics*                                                                                                                                                       
  UPS                                2 (0.5%)                                                   23 (2.9%)     427 (9.6%)      774 (13.4%)     273 (20.3%)     40 (35·4%)   **\<0.001**
  LMS                                7 (1.9%)                                                   44 (5.7%)     1,038 (23.3%)   1,359 (23.5%)   314 (23.4%)     16 (14·2%)   **\<0.001**
  Myxofibrosarcoma                   2 (0.5%)                                                   8 (1.0%)      214 (4.8%)      445 (7.7%)      135 (10.1%)     14 (12·4%)   **\<0.001**
  Angiosarcoma                       8 (2.2%)                                                   35 (4.5%)     194 (4.4%)      324 (5.6%)      105 (7.8%)      12 (10·6%)   **\<0.001**
  DDLPS                              0 (0%)                                                     10 (1.3%)     412 (9.3%)      892 (15.4%)     192 (14.3%)     11 (9·7%)    **\<0.001**
  Undifferentiated sarcoma           11 (2.9%)                                                  40 (5.2%)     245 (13.2%)     369 (6.4%)      103 (7.7%)      10 (8·8%)    **0.002**
  Pleomorphic RMS                    0 (0.0%)                                                   6 (0.8%)      23 (0.7%)       32 (0.5%)       6 (0.4%)        1 (0.9%)     0.64
  *GIST*                             2 (0.5%)                                                   20 (2.6%)     496 (11.1%)     859 (14.8%)     113 (8.4%)      6 (5.3%)     **\<0.001**
  Translocation sarcoma                                                                                                                                                    
  Ewing                              85 (23.2%)                                                 94 (12.2%)    93 (2.1%)       34 (0.5%)       5 (0.4%)        1 (0·9%)     **\<0.001**
  Myxoid LPS                         7 (1.9%)                                                   61 (7.9%)     307 (6.8%)      99 (1.7%)       10 (0.7%)       1 (0·9%)     **\<0.001**
  Synovial sarcoma                   39 (10.6%)                                                 144 (18.6%)   322 (7.2%)      114 (1.9%)      16 (1.2%)       1 (0·9%)     **\<0.001**
  Other/not specified                203 (55.3%)                                                287 (37.2%)   1,080 (24.2%)   488 (8.4%)      71 (5.3%)       0 (0%)       **\<0.001**
  Gender                                                                                                                                                                   
  Female                             153 (41.7%)                                                362 (46.9%)   2,355 (52.9%)   2,759 (47.7%)   654 (48.7%)     62 (54.9%)   **\<0.001**
  Male                               214 (58.3%)                                                410 (51.3%)   2096 (47.1%)    3,030 (52.3%)   689 (51.3%)     51 (45.1%)   
  Grade                                                                                                                                                                    
  1                                  9 (2.5%)                                                   68 (8.8%)     513 (11.5%)     418 (7.2%)      78 (5.8%)       6 (5.3%)     **\<0.001**
  2                                  28 (7.6%)                                                  130 (16.8%)   1,081 (24.3%)   1,541 (26.6%)   353 (26.3%)     24 (21.2%)   
  3                                  136 (37.1%)                                                195 (25.3%)   1,219 (27.4%)   1,735 (30.0%)   515 (38.3%)     39 (34.5%)   
  UNK/NA                             194 (52.8%)                                                379 (49.1%)   1,638 (36.8%)   2095 (36.2%)    397 (29.6)      44 (38.9%)   
  Depth                                                                                                                                                                    
  Deep                               176 (47.9%)                                                488 (63.2%)   3,523 (79.2%)   4,361 (75.3%)   894 (66.5%)     63 (55.7%)   **\<0.001**
  Superficial                        15 (4.1%)                                                  70 (9.1%)     543 (12.2%)     896 (15.5%)     349 (26.0%)     45 (39.8%)   
  Unknown                            176 (48.0%)                                                214 (27.7%)   385 (8.6%)      532 (9.2%)      240 (17.8%)     5 (4.4%)     
  Size in mm (median)                69.1                                                       72.7          70.2            75.5            69.7            8.0          **0.002**
  Metastatic at diagnosis                                                                                                                                                  
  Yes                                96 (26.1%)                                                 155 (20.1%)   658 (14.7%)     831 (14.3%)     146 (10.8%)     6 (5.3%)     **\<0.001**
  No                                 233 (63.5%)                                                557 (72.2%)   3,406 (76.5%)   4,430 (76.5%)   1,038 (77.3%)   89 (78.8%)   
  Unknown                            38 (10.4%)                                                 60 (7.8%)     387 (8.7%)      528 (9.1%)      159 (11.8%)     18 (15.9%)   
  Biopsy before                                                                                                                                                            
  Yes                                299 (81.5%)                                                555 (71.9%)   763 (62.1%)     3,690 (63.7%)   906 (87.5%)     72 (63.7%)   **\<0.001**
  No                                 35 (9.5%)                                                  162 (21.0%)   1,365 (30.7%)   1,644 (28.4%)   346 (25.8%)     32 (28.3%)   
  Unknown                            33(9.0%)                                                   55 (7.1%)     323 (7.3%)      455 (7.9%)      91 (6.8%)       9 (8.0%)     
  Imaging \< surgery                                                                                                                                                       
  Yes                                311 (84.7%)                                                639 (82.8%)   3,406 (76.5%)   4,281 (74.0%)   915 (68.1%)     64 (66.6%)   **\<0.001**
  No                                 8 (2.2%)                                                   29 (3.8%)     199 (4.5%)      326 (5.8%)      128 (9.5%)      14 (12.4%)   
  Unknown                            48 (13.1%)                                                 104 (13.5%)   846 (19.0%)     1,172 (20.2%)   300 (22.3%)     35 (31.0%)   
  Neoadjuvant treat                                                                                                                                                        
  Yes                                82 (22.3%)                                                 82 (10.6%)    310 (7.0%)      325 (5.6%)      36 (2.7%)       3 (2.7%)     **\<0.001**
  No                                 25 (6.8%)                                                  139 (18.0%)   981 (22.0%)     1,308 (22.6%)   277 (20.6%)     31 (27.4%)   
  Total                              260 (70.8%)                                                551 (71.4%)   3,160 (71.0%)   4,156 (71.8%)   1,030 (76.7%)   79 (69.9%)   
  Surgery in NETSARC                                                                                                                                                       
  Yes                                146 (39.8%)                                                291 (37.7%)   1,529 (34.4%)   1849 (31.9%)    351 (26.1%)     16 (14.2%)   **\<0.001**
  No/No surgery/UNK                  221 (60.2%)                                                481 (62.3%)   2,922 (65.6%)   3,940 (68.1%)   992 (73.9%)     97 (85.8%)   
  Excision margins of last surgery                                                                                                                                         
  R0                                 122 (33.2%)                                                307 (39.8%)   1,799 (40.4%)   2,229 (38.5%)   392 (29.2%)     29 (25.7%)   **\<0.001**
  R1                                 47 (12.5%)                                                 105 (13.6%)   721 (16.2%)     997 (17.2%)     254 (18.9%)     18 (15.9%)   
  R2                                 9 (2.5%)                                                   42 (5.4%)     197 (4.4%)      235 (4.1%)      58 (4.3%)       7 (6.2%)     
  Other/Unknown                      189 (51.5%)                                                318 (41.2%)   1,734 (38.9%)   2,328 (40.2%)   639 (47.6%)     59 (52.2%)   

Bold indicates significant p value (*p* \< 0.05).

Chi^2^ test.

Surgery was less frequently performed in patients over 90 years (60.2% *vs*. 78.3%, *p* ≤ 0.001); they also had less frequently neoadjuvant treatment. This did not result in significant differences in terms of resection margins at first or at second surgery (Table [2](#ijc32307-tbl-0002){ref-type="table"}). Resection rates (Table [2](#ijc32307-tbl-0002){ref-type="table"}) and final result of the surgical removal (Table [3](#ijc32307-tbl-0003){ref-type="table"}) were also not significantly different when comparing only patients for whom the R criterion was documented.

Patients over 90 as compared to other age groups {#ijc32307-sec-0008}
------------------------------------------------

Table [3](#ijc32307-tbl-0003){ref-type="table"} presents an analytic description of histologies, clinical presentations and management within different age subgroups. As expected, histological subtypes were extremely different across age groups, in particular across the extremes. It is interesting to note that differences were also observed in the three elder groups, on histologies, depth, grade and metastasis. As compared to the 80--90 years group, histotypes, depth, metastasis at diagnosis and gender of patient with sarcoma aged \>90 were different (Table [3](#ijc32307-tbl-0003){ref-type="table"}). Regarding patient management, compliance to CPGs was the lowest in patients aged \>90, together with the final quality of surgery (lowest R0 rate, highest R2 rate), with fewer patients operated in reference centers. Overall a significant trend of decrease of compliance to guidelines, management in reference centers and final quality of surgery over age groups was observed, from the children and adolescent/young adults to the older age group (Table [3](#ijc32307-tbl-0003){ref-type="table"}).

Relapse and survival {#ijc32307-sec-0009}
--------------------

Local progression‐free survival (PFS), metastatic PFS and PFS were not significantly different in the two populations (Figs. [1](#ijc32307-fig-0001){ref-type="fig"} *a*--[1](#ijc32307-fig-0001){ref-type="fig"} *c*). Relapse‐free survival of patients aged over 90 *vs*. those aged 90 or under was also similar when the analysis was conducted only with operated patients (Fig. [1](#ijc32307-fig-0001){ref-type="fig"} *d*). No difference was observed either for local relapse‐free survival not for metastatic relapse‐free survival for operated patients (data not shown). As expected, overall survival was worse in patients \>90 (Fig. [1](#ijc32307-fig-0001){ref-type="fig"} *e*). Importantly, the overall survival of patients who were not operated was significantly worse in patients aged over 90 *vs*. younger patients (9.9 *vs*. 27.1 months, *p* \< 0.001) with no patient alive at 3 years in the older group *vs*. 40% in the younger one (Fig. [1](#ijc32307-fig-0001){ref-type="fig"} *f*). Using Cox model, with grade, size, depth, site, gender, presentation to a multidisciplinary team (MDT) prior to treatment[5](#ijc32307-bib-0005){ref-type="ref"} and surgery in expert center[12](#ijc32307-bib-0012){ref-type="ref"} and age \>90 as tested variables, age \>90 was not identified as an independent prognostic factor for either relapse‐free survival or PFS (data not shown).

![Progression, relapse and survival in sarcoma patients aged over or under 90. (*a*) Local progression‐free survival of patients aged over 90 (green) and younger (blue). (*b*) Metastatic progression‐free survival of patients aged over 90 (green) and younger (blue). (*c*) Progression‐free survival of patients aged over 90 (green) and younger (blue). (*d*) Relapse‐free survival of operated patients aged over 90 (green) and younger (blue). (*e*) Overall survival of patients aged over 90 (green) and younger (blue). (*f*) Overall survival of nonoperated patients aged over 90 (green) and younger (blue). \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](IJC-145-2135-g001){#ijc32307-fig-0001}

Discussion {#ijc32307-sec-0010}
==========

This analysis of a 6‐year nationwide registry of incident sarcoma patients includes over 12,000 patients with 113 (0.9%) patients aged \>90. It identifies for the first time‐specific pathological and clinical characteristics of sarcomas diagnosed in patients over 90: these are almost exclusively sarcomas with complex genomics, more frequently superficial tumors, from limb sites or head and neck sites. Despite an obvious difference in life duration, sarcoma patients aged over 90 do not have a higher frequency of previous radiotherapy, previous cancers, and none genetic predisposing condition. Patients aged over 90 are also less frequently metastatic at initial presentation than the younger sarcoma patient population and relative to the sex ratio at this age in the French population, more frequently males. These clinicopathological and clinical specificities of sarcomas occurring at an older age are unexpected and had not been previously recognized to our knowledge. It is interesting to observe that these characteristics are not equally shared by the groups aged 60--80 or 80--90, but quite characteristic of this age group. Sarcomas occurring in higher age may result in more from accumulation of external oncogenic events over the lifetime; limb and head and neck sites may suggest exposure to the sun as risk factors to be tested. It is particularly notable that less than 3% of sarcoma in this population was translocation‐related sarcomas.

Less adequate management is offered to patients with STS over 90, in particular regarding pretreatment imaging and surgery. Of note, oncogeriatric assessment[13](#ijc32307-bib-0013){ref-type="ref"} is not part of the NETSARC data set, and it is likely that coexisting conditions have largely contributed to these differences with younger patients. However, when patients over 90 are treated with surgery according to clinical practice guidelines (within NETSARC, the ESMO guidelines are used as reference),[2](#ijc32307-bib-0002){ref-type="ref"}, [3](#ijc32307-bib-0003){ref-type="ref"} relapse‐free survival and PFS remain similar to that of the younger population in univariate and also multivariate analysis where classical prognostic factors are introduced.[2](#ijc32307-bib-0002){ref-type="ref"}, [3](#ijc32307-bib-0003){ref-type="ref"}, [5](#ijc32307-bib-0005){ref-type="ref"} This points to the need not to undertreat patients, including those aged over 90, and to adopt the classical CPGs for sarcoma management in patients at all age when oncogeriatric status allows. As expected, the overall survival of sarcoma patients aged over 90 is shorter than that of younger patients. Median overall survival is 25 months in this population of patients over 90 (whose median age is 92), an outcome which must be compared to the 50 months life expectancy for the general French population at the age of 90.[14](#ijc32307-bib-0014){ref-type="ref"}

To the best of our knowledge, this is the first series reporting on the different biology and natural history of patients with sarcomas occurring at a very high age. Sarcoma occurring after 90 has a specific biology and natural history, but not intrinsically a worse cancer‐specific prognosis. If fit according to geriatric assessment, this patient population, should be treated according to the general CPGs for sarcomas. It is reasonable to infer a similar statement for younger geriatric sarcoma patients.

The authors would like to thank the teams and leaders of the French National Cancer Institute (INCa) for the continuous support to the project.
